APA (7th ed.) Citation

EM, S., JE, M., E, O., V, C., Y, L., D, C., . . . ES, Y. (2021). An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer. Breast cancer research : BCR, 23(1), 30. https://doi.org/10.1186/s13058-021-01408-9

Chicago Style (17th ed.) Citation

EM, Stringer-Reasor, et al. "An Open-label, Pilot Study of Veliparib and Lapatinib in Patients with Metastatic, Triple-negative Breast Cancer." Breast Cancer Research : BCR 23, no. 1 (2021): 30. https://doi.org/10.1186/s13058-021-01408-9.

MLA (9th ed.) Citation

EM, Stringer-Reasor, et al. "An Open-label, Pilot Study of Veliparib and Lapatinib in Patients with Metastatic, Triple-negative Breast Cancer." Breast Cancer Research : BCR, vol. 23, no. 1, 2021, p. 30, https://doi.org/10.1186/s13058-021-01408-9.